Accuray (ARAY) vs CVRx (CVRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
CVRx (CVRX) has outperformed Accuray (ARAY) over the past year, losing 81.6% versus a loss of 85.6%. Over five years, CVRX leads with a -89.3% price change compared with -93.9% for ARAY. CVRx is the larger company by market cap ($44.8 million vs $28.8 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARAY | CVRX |
|---|---|---|
| Share price | $0.2414 | $1.68 |
| Market cap | $28.83M | $44.76M |
| 1-day change | -4.74% | +0.60% |
| YTD return | -70.56% | -76.34% |
| 1-year return | -85.63% | -81.56% |
| 5-year return | -93.86% | -89.27% |
| EPS (TTM) | $-0.40 | $-1.96 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.10 | $11.30 |
| 52-week low | $0.22 | $1.50 |
| Distance from 52-week high | -88.50% | -85.13% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +172.62% |
| Average volume | 7.19M | 922.12K |
| Shares outstanding | 119.44M | 26.64M |
| Employees | 809 | 223 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Accuray
ARAY stock →Accuray Incorporated engages in the design, development, and sale of radiosurgery and radiation therapy systems for the treatment of tumors throughout the body in the United States, Canada, Latin America, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. The company offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.
Healthcare · Medical Devices · 809 employees
About CVRx
CVRX stock →CVRx, Inc., a commercial-stage medical device company, engages in developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases in the United States, Germany, and internationally. The company offers Barostim, an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery to counteract decreased baroreceptor signaling, and provides baroreflex activation therapy, which links the cardiovascular system to the autonomic nervous system.
Healthcare · Medical Devices · 223 employees
ARAY vs CVRX FAQ
Which is bigger, Accuray or CVRx?
CVRx (CVRX) is larger, with a market capitalization of $44.76M compared with $28.83M for Accuray (ARAY).
Which stock has performed better over the past year, ARAY or CVRX?
CVRX returned -81.56% over the past 12 months, compared with -85.63% for ARAY (price return, excluding dividends). Past performance does not predict future results.
Are Accuray and CVRx in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.